image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.1975
-4.28 %
$ 17.1 M
Market Cap
-0.2
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one XAIR stock under the worst case scenario is HIDDEN Compared to the current market price of 0.198 USD, Beyond Air, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one XAIR stock under the base case scenario is HIDDEN Compared to the current market price of 0.198 USD, Beyond Air, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one XAIR stock under the best case scenario is HIDDEN Compared to the current market price of 0.198 USD, Beyond Air, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart XAIR

image
$0.7$0.7$0.7$0.7$0.6$0.6$0.6$0.6$0.5$0.5$0.5$0.5$0.4$0.4$0.4$0.4$0.3$0.3$0.3$0.3$0.2$0.2$0.2$0.215 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
1.16 M REVENUE
0.00%
-63 M OPERATING INCOME
-22.33%
-60.2 M NET INCOME
-1.42%
-56 M OPERATING CASH FLOW
-69.69%
-12.2 M INVESTING CASH FLOW
40.57%
43.2 M FINANCING CASH FLOW
1501.15%
1.07 M REVENUE
34.34%
-11 M OPERATING INCOME
14.66%
-13.3 M NET INCOME
10.41%
-7.73 M OPERATING CASH FLOW
42.07%
-6.94 M INVESTING CASH FLOW
-42.96%
-9.21 M FINANCING CASH FLOW
-42.61%
Balance Sheet Beyond Air, Inc.
image
Current Assets 43.9 M
Cash & Short-Term Investments 34.5 M
Receivables 548 K
Other Current Assets 8.92 M
Non-Current Assets 13 M
Long-Term Investments 0
PP&E 11.5 M
Other Non-Current Assets 1.54 M
60.51 %15.66 %20.16 %Total Assets$57.0m
Current Liabilities 11.6 M
Accounts Payable 1.95 M
Short-Term Debt 1.22 M
Other Current Liabilities 8.4 M
Non-Current Liabilities 18.2 M
Long-Term Debt 16.6 M
Other Non-Current Liabilities 1.59 M
6.54 %4.09 %28.21 %55.82 %5.34 %Total Liabilities$29.8m
EFFICIENCY
Earnings Waterfall Beyond Air, Inc.
image
Revenue 1.16 M
Cost Of Revenue 2.47 M
Gross Profit -1.31 M
Operating Expenses 61.7 M
Operating Income -63 M
Other Expenses -2.76 M
Net Income -60.2 M
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)1m(2m)(1m)(62m)(63m)3m(60m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-112.77% GROSS MARGIN
-112.77%
-5436.24% OPERATING MARGIN
-5436.24%
-5197.76% NET MARGIN
-5197.76%
-240.51% ROE
-240.51%
-105.76% ROA
-105.76%
-135.17% ROIC
-135.17%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Beyond Air, Inc.
image
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)20152015201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -60.2 M
Depreciation & Amortization 2.35 M
Capital Expenditures -5.74 M
Stock-Based Compensation 21.3 M
Change in Working Capital -16 M
Others -18.1 M
Free Cash Flow -61.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Beyond Air, Inc.
image
Wall Street analysts predict an average 1-year price target for XAIR of $1 , with forecasts ranging from a low of $1 to a high of $1 .
XAIR Lowest Price Target Wall Street Target
1 USD 406.33%
XAIR Average Price Target Wall Street Target
1 USD 406.33%
XAIR Highest Price Target Wall Street Target
1 USD 406.33%
Price
Max Price Target
Min Price Target
Average Price Target
1111111111000000Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Beyond Air, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
252 K USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
3.01 M USD 2
6-9 MONTHS
93.9 K USD 3
9-12 MONTHS
7. News
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism The FDA d esignation m arks a s ignificant m ilestone in the d evelopment of a n ovel t reatment for a r are n eurodevelopmental d isorder globenewswire.com - 4 weeks ago
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer's Disease Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer's Disease globenewswire.com - 1 month ago
Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home GARDEN CITY, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the publication of its scientific article, “A Pilot Study to Assess the Effect of Intermittent Inhaled Nitric Oxide as Treatment of Nontuberculous Mycobacteria Lung Infection” in Annals of the American Thoracic Society, an online peer-reviewed journal. The article is available online at (click here). globenewswire.com - 1 month ago
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology globenewswire.com - 1 month ago
Beyond Oil Announces Start of Commercialization of India Distribution Agreement; First Payment Received Beyond Oil announces successful initiation of first order under new distribution agreement focusing on Indian markets, with full payment received for upcoming 6T shipment Beyond Oil announces successful initiation of first order under new distribution agreement focusing on Indian markets, with full payment received for upcoming 6T shipment globenewswire.com - 1 month ago
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer's disease and brain cancers, and a subsidiary of Beyond Air (NASDAQ: XAIR), has secured an initial $2 million in equity financing from private investors as part of a larger funding round. This investment will accelerate the preclinical development of NeuroNOS's small-molecule drug, designed as an injectable or oral treatment for children with autism. globenewswire.com - 1 month ago
Beyond Oil Announces First Distribution Agreement in Portugal Distribution Agreement with Serious Formula Ltd. establishes Beyond Oil's presence in the Portuguese market; Agreement includes a five-year expected minimum purchase commitment plan amounting to €1.13 million Distribution Agreement with Serious Formula Ltd. establishes Beyond Oil's presence in the Portuguese market; Agreement includes a five-year expected minimum purchase commitment plan amounting to €1.13 million globenewswire.com - 2 months ago
Beyond Oil Announces Strategic Investment at a Premium to Market Price by Clal Insurance, a Leading Israeli Institutional Investor, as Part of Potential Uplisting to a Senior Exchange Clal Insurance to invest approximately CAD $10.5 million in Beyond Oil at a 10% premium to its stock market trading price, with potential follow-on investment through the exercise of warrants; Beyond Oil commits to pursuing a potential uplisting to a senior exchange in Canada or the U.S. Clal Insurance to invest approximately CAD $10.5 million in Beyond Oil at a 10% premium to its stock market trading price, with potential follow-on investment through the exercise of warrants; Beyond Oil commits to pursuing a potential uplisting to a senior exchange in Canada or the U.S. globenewswire.com - 2 months ago
Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N.Y., March 11, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, announced the expansion of its global distribution channels for LungFit PH with several new distribution agreements that will cover four countries, including France, Romania, Turkey and Morocco. globenewswire.com - 2 months ago
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Roth 37th Annual Growth Stock Conference being held March 16-18, 2025 in Laguna, CA and the Jones Healthcare and Technology Innovation Conference being held April 8-9, 2025 in Las Vegas, NV. globenewswire.com - 2 months ago
Beyond Oil Enters Indian Market with Significant Distribution Agreement Strategic agreement to introduce Beyond Oil's innovative frying oil filtration solution to restaurants across India Strategic agreement to introduce Beyond Oil's innovative frying oil filtration solution to restaurants across India globenewswire.com - 2 months ago
Beyond Oil Announces First Distribution Agreement in South Africa New Agreement with Minrosolve Proprietary Marks an Important Milestone in Beyond Oil's Accelerating Global Expansion New Agreement with Minrosolve Proprietary Marks an Important Milestone in Beyond Oil's Accelerating Global Expansion globenewswire.com - 2 months ago
8. Profile Summary

Beyond Air, Inc. XAIR

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 17.1 M
Dividend Yield 0.00%
Description Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Contact 900 Stewart Avenue, Garden City, NY, 11530 https://www.beyondair.net
IPO Date June 12, 2018
Employees 107
Officers Mr. Steven Adam Lisi Chief Executive Officer & Chairman of the Board Mr. Michael A. Gaul Chief Operating Officer Dr. John Jett Ph.D. Head of Research & Clinical Development Mr. Adam Newman Corporate Secretary Mr. David R. Webster Chief Commercial Officer Mr. Amir Avniel Chief Executive Officer of NeuroNOS Dr. Andrew R. Colin M.D. Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board Mr. Douglas Quinton Larson Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer